A Heart-Protective Drug May Change the Long-Term Future of Childhood Cancer Survivors
A major long-term study suggests that dexrazoxane, a drug used to protect the heart during chemotherapy, can substantially reduce cardiac damage in children treated for cancer. The findings, based on survivors followed into young adulthood and beyond, indicate that the benefits of the drug may persist for at least 15 years after chemotherapy ends. Researchers say the results could eventually influence how doctors monitor survivors throughout their lives, while offering reassurance to families concerned about the delayed effects of cancer treatment.
The study examined nearly 900 childhood cancer survivors who had received doxorubicin, an anthracycline chemotherapy drug used to treat leukemia, lymphoma and sarcoma. Anthracyclines remain among the most effective cancer medicines, but they are also strongly associated with long-term heart injury. Approximately half of the patients in the study received dexrazoxane alongside their chemotherapy, while the others did not. The participants were monitored with echocardiograms, which use ultrasound to measure the heart’s structure and pumping performance.
The research grew out of the Children’s Oncology Group ALTE11C2 clinical trial, originally led by investigators including Eric Chow of Fred Hutchinson Cancer Center and Steven Lipshultz of the University at Buffalo. Erin Mobley, an assistant professor of surgery at the University of Florida College of Medicine in Jacksonville, served as first author of the new analysis. The researchers included 230 survivors who had been followed for at least 10 years, with nearly 200 monitored for more than 15 years after treatment.
Doxorubicin can damage cardiac muscle through several biological pathways. The drug interferes with topoisomerase IIβ, an enzyme found in heart cells, and can also promote oxidative stress and injury to cellular structures responsible for producing energy. Over time, this damage may cause the heart chambers to enlarge and the muscle to weaken. In some survivors, the deterioration can progress to cardiomyopathy, a condition in which the heart cannot pump blood efficiently, eventually increasing the risk of heart failure.
Dexrazoxane was developed to reduce this type of injury. The drug can bind iron and limit chemical reactions that generate damaging free radicals during anthracycline treatment. It also appears to reduce harmful interactions between doxorubicin and topoisomerase IIβ in heart cells. By protecting cardiac tissue while allowing chemotherapy to attack cancer cells, dexrazoxane aims to preserve the heart’s ability to function long after treatment has finished.
In the new study, survivors who received dexrazoxane had significantly healthier cardiac measurements years after chemotherapy than those who did not receive the protective drug. Their echocardiograms showed more favorable heart function, and many were categorized as having a moderate rather than high risk of treatment-related cardiac complications. The difference is important because heart damage from anthracyclines may remain silent for years before symptoms appear. A patient can feel healthy while subtle changes in the heart’s size, shape or pumping ability are already developing.
The results may also affect the way survivors are followed as they age. Current survivorship care often includes periodic echocardiograms, with the frequency determined by factors such as the cumulative chemotherapy dose, age at treatment and whether other therapies could have affected the heart. If future studies confirm that dexrazoxane produces durable protection, survivors who received it might not require the same intensity of lifelong cardiac screening as those exposed to anthracyclines without protection. Researchers stress, however, that the findings do not yet justify changing clinical guidelines.
Long-term surveillance remains essential because the participants are still relatively young. The researchers want to determine whether the cardiac advantages associated with dexrazoxane remain visible as survivors enter their 50s and 60s, when cardiovascular disease becomes more common for reasons unrelated to cancer treatment. Blood pressure, obesity, diabetes, smoking, physical inactivity and other medical conditions may interact with earlier chemotherapy-related injury. Continuing to follow this population could reveal whether dexrazoxane prevents only early changes in heart function or also reduces the risk of clinically apparent heart failure later in life.
The findings carry particular significance for children because developing organs may be especially vulnerable to chemotherapy-related injury. Childhood cancer survivors can live for many decades after treatment, meaning that even a modest reduction in cardiac damage could translate into a substantial improvement in lifetime health. Mobley, herself a survivor who received anthracyclines as a child, said the research could help families envision life after cancer with greater confidence. The study does not eliminate the cardiovascular risks associated with chemotherapy, but it suggests that a treatment given during cancer therapy may continue protecting the heart long after the cancer has been defeated.
Subject of Research: People
Article Title: Longitudinal Change in Cardiac Function After Doxorubicin and Dexrazoxane: A Report From Children’s Oncology Group ALTE11C2
News Publication Date: 6 August 2026
Web References: https://ascopubs.org/doi/10.1200/JCO-26-00260
References: Journal of Clinical Oncology; DOI: 10.1200/JCO-26-00260
Keywords: Childhood cancer, cancer survivors, dexrazoxane, doxorubicin, anthracyclines, cardiotoxicity, heart damage, cardioprotection, pediatric oncology, chemotherapy, echocardiography, survivorship care
